Do Its Financials Have Any Role To Play In Driving Guangdong Jiaying Pharmaceutical Co., Ltd's (SZSE:002198) Stock Up Recently?
Do Its Financials Have Any Role To Play In Driving Guangdong Jiaying Pharmaceutical Co., Ltd's (SZSE:002198) Stock Up Recently?
Most readers would already be aware that Guangdong Jiaying Pharmaceutical's (SZSE:002198) stock increased significantly by 18% over the past week. As most would know, fundamentals are what usually guide market price movements over the long-term, so we decided to look at the company's key financial indicators today to determine if they have any role to play in the recent price movement. In this article, we decided to focus on Guangdong Jiaying Pharmaceutical's ROE.
大多數讀者已經意識到，廣東嘉應藥業（SZSE: 002198）的股票在過去一週大幅上漲了18％。正如大多數人所知道的那樣，基本面通常是長期指導市場價格走勢的因素，因此我們決定今天查看公司的關鍵財務指標，以確定它們在最近的價格走勢中是否可以發揮任何作用。在本文中，我們決定重點關注廣東嘉應藥業的投資回報率。
ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.
投資回報率或股本回報率是評估公司如何有效地從股東那裏獲得投資回報的有用工具。簡而言之，投資回報率顯示了每美元從其股東投資中產生的利潤。
View our latest analysis for Guangdong Jiaying Pharmaceutical
查看我們對廣東嘉應藥業的最新分析
How To Calculate Return On Equity?
如何計算股本回報率？
The formula for ROE is:
這個 投資回報率公式 是：
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
股本回報率 = 淨利潤（來自持續經營）≥ 股東權益
So, based on the above formula, the ROE for Guangdong Jiaying Pharmaceutical is:
因此，根據上述公式，廣東佳英藥業的投資回報率爲：
7.2% = CN¥54m ÷ CN¥741m (Based on the trailing twelve months to March 2023).
7.2% = 5400萬人民幣 ⇒ 7.41億元人民幣（基於截至2023年3月的過去十二個月）。
The 'return' is the profit over the last twelve months. So, this means that for every CN¥1 of its shareholder's investments, the company generates a profit of CN¥0.07.
“回報” 是過去十二個月的利潤。因此，這意味着其股東每投資1元人民幣，公司就會產生0.07元人民幣的利潤。
What Is The Relationship Between ROE And Earnings Growth?
投資回報率與收益增長之間有甚麼關係？
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.
我們已經確定，投資回報率是衡量公司未來收益的有效盈利指標。然後，我們能夠評估公司的收益增長潛力，具體取決於公司對這些利潤進行再投資或 “保留” 了多少及其有效性。假設其他一切保持不變，那麼與不一定具有這些特徵的公司相比，投資回報率和利潤保留率越高，公司的增長率就越高。
Guangdong Jiaying Pharmaceutical's Earnings Growth And 7.2% ROE
廣東嘉應藥業的收益增長和 7.2% 的投資回報率
On the face of it, Guangdong Jiaying Pharmaceutical's ROE is not much to talk about. However, given that the company's ROE is similar to the average industry ROE of 8.8%, we may spare it some thought. Particularly, the exceptional 49% net income growth seen by Guangdong Jiaying Pharmaceutical over the past five years is pretty remarkable. Given the slightly low ROE, it is likely that there could be some other aspects that are driving this growth. Such as - high earnings retention or an efficient management in place.
從表面上看，廣東嘉應藥業的投資回報率並不多。但是，鑑於該公司的投資回報率與8.8％的平均行業投資回報率相似，我們可以省略一下。特別是，廣東嘉應藥業在過去五年中實現了49％的驚人淨收入增長，這非常引人注目。鑑於投資回報率略低，可能還有其他一些方面在推動這種增長。例如-高收益留存率或有效的管理。
We then compared Guangdong Jiaying Pharmaceutical's net income growth with the industry and we're pleased to see that the company's growth figure is higher when compared with the industry which has a growth rate of 8.8% in the same 5-year period.
然後，我們將廣東嘉應藥業的淨收入增長與該行業進行了比較，我們很高興地看到，與同期增長率爲8.8％的行業相比，該公司的增長數字更高。
The basis for attaching value to a company is, to a great extent, tied to its earnings growth. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). This then helps them determine if the stock is placed for a bright or bleak future. If you're wondering about Guangdong Jiaying Pharmaceutical's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.
爲公司增值的基礎在很大程度上與其收益增長息息相關。對於投資者來說，重要的是要知道市場是否對公司的預期收益增長（或下降）進行了定價。然後，這可以幫助他們確定股票是爲光明的未來還是暗淡的未來準備的。如果你想知道廣東佳英藥業的估值，可以看看這個衡量其與行業相比的市盈率指標。
Is Guangdong Jiaying Pharmaceutical Making Efficient Use Of Its Profits?
廣東嘉應藥業是否在有效利用利潤？
Given that Guangdong Jiaying Pharmaceutical doesn't pay any dividend to its shareholders, we infer that the company has been reinvesting all of its profits to grow its business.
鑑於廣東嘉應藥業沒有向股東支付任何股息，我們推斷該公司一直在將其所有利潤再投資以發展業務。
Conclusion
結論
In total, it does look like Guangdong Jiaying Pharmaceutical has some positive aspects to its business. With a high rate of reinvestment, albeit at a low ROE, the company has managed to see a considerable growth in its earnings.
總的來說，看來廣東嘉應藥業的業務確實有一些積極的方面。由於再投資率很高，儘管投資回報率很低，但該公司的收益卻取得了可觀的增長。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎？對內容感到擔憂？ 取得聯繫 直接和我們聯繫。 或者，給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是一般性的。 我們僅使用公正的方法提供基於歷史數據和分析師預測的評論，我們的文章無意提供財務建議。 它不構成買入或賣出任何股票的建議，也沒有考慮您的目標或財務狀況。我們的目標是爲您提供由基本面數據驅動的長期重點分析。請注意，我們的分析可能未將最新的價格敏感型公司公告或定性材料考慮在內。簡而言之，華爾街對上述任何股票都沒有頭寸。